Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharmaceutical Partners (CPRX)
:CPRX
CPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.47 - $24.64
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.07M
Market Cap
$2.51B
Enterprise Value$2.05B
Total Cash (Recent Filing)$517.55M
Total Debt (Recent Filing)$3.19M
Price to Earnings (P/E)15.8
Beta1.18
Next Earnings
May 07, 2025EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.31
Shares Outstanding121,449,650
10 Day Avg. Volume1,383,926
30 Day Avg. Volume1,071,142
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)N/A
Price to Sales (P/S)5.42
Price to Cash Flow (P/CF)9.40
P/FCF Ratio9.40
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.86
Enterprise Value/Ebitda9.60
Forecast
1Y Price Target
$33.83Price Target Upside63.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Catalyst Pharma News
PremiumCompany Announcements
Catalyst Pharmaceuticals Reports Record 2024 Financial ResultsPremiumCompany Announcements
Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Litigation OutcomesSuccessful settlements in patent litigation with Teva and positive indications from Lupin bolster confidence in Catalyst's ability to defend its intellectual property.
Market PositioningAgamree is well-positioned to benefit from the recent genericization of competitor Emflaza, supporting a strong launch in the DMD market.
Bears Say
CompetitionFycompa sales are likely to be negatively impacted by generic entry, affecting revenue growth.
---
Ownership Overview
6.34% Insiders
17.52% Mutual Funds
16.84% Other Institutional Investors
33.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CPRX FAQ
What was Catalyst Pharmaceutical Partners’s price range in the past 12 months?
Catalyst Pharmaceutical Partners lowest stock price was $14.47 and its highest was $24.64 in the past 12 months.
What is Catalyst Pharmaceutical Partners’s market cap?
Catalyst Pharmaceutical Partners’s market cap is $2.51B.
When is Catalyst Pharmaceutical Partners’s upcoming earnings report date?
Catalyst Pharmaceutical Partners’s upcoming earnings report date is May 07, 2025 which is in 56 days.
How were Catalyst Pharmaceutical Partners’s earnings last quarter?
Catalyst Pharmaceutical Partners released its earnings results on Feb 26, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.339 by $0.101.
Is Catalyst Pharmaceutical Partners overvalued?
According to Wall Street analysts Catalyst Pharmaceutical Partners’s price is currently Undervalued.
Does Catalyst Pharmaceutical Partners pay dividends?
Catalyst Pharmaceutical Partners does not currently pay dividends.
What is Catalyst Pharmaceutical Partners’s EPS estimate?
Catalyst Pharmaceutical Partners’s EPS estimate is 0.34.
How many shares outstanding does Catalyst Pharmaceutical Partners have?
Catalyst Pharmaceutical Partners has 121,449,650 shares outstanding.
What happened to Catalyst Pharmaceutical Partners’s price movement after its last earnings report?
Catalyst Pharmaceutical Partners reported an EPS of $0.44 in its last earnings report, beating expectations of $0.339. Following the earnings report the stock price went up 5.248%.
Which hedge fund is a major shareholder of Catalyst Pharmaceutical Partners?
Currently, no hedge funds are holding shares in CPRX
---
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (63.67% Upside)
$33.83 (63.67% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.20%
12-Months-Change
Fundamentals
Return on Equity
29.38%
Trailing 12-Months
Asset Growth
81.07%
Trailing 12-Months
Company Description
Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.
---
CPRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful product launches, particularly with AGAMREE and FIRDAPSE, supported by a strong financial position and favorable patent resolution. However, there are challenges with anticipated revenue decline for FYCOMPA due to patent expiry, increased SG&A expenses, and expected impacts from the Inflation Reduction Act.Read More>---
CPRX Stock 12 Month Forecast
Average Price Target
$33.83
▲(63.67% Upside)
Technical Analysis
Amgen
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering CPRX
1 Year
1 Year Success Rate
18/24 ratings generated profit
1 Year Average Return
+44.20%
reiterated a buy rating 13 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +44.20% per trade.
---